论文部分内容阅读
聚腺苷二磷酸核糖聚合酶(PARP)抑制剂可选择性杀死同源重组功能缺陷的肿瘤细胞,而对正常细胞的危害较小,这是“合成致死”理论应用于临床的典型范例。尽管PARP抑制剂作为一种新型靶向药物,极具应用潜力,但其临床应用也面临诸多问题,其中耐药性的产生被认为是限制PARP抑制剂临床应用的重要原因之一。简介PARP-1的功能及PARP-1抑制剂研究进展,着重综述PARP-1抑制剂耐药的临床表现、可能的发生机制及逆转策略,为PARP-1抑制剂的临床合理应用提供参考。
Poly (ADP-ribose) polymerase (PARP) inhibitors can selectively kill tumor cells with homologous recombination defects but have less harm to normal cells, which is the typical application of “synthetic lethality” theory in clinical practice example. Although PARP inhibitors have potential application as a new targeted drug, their clinical application also faces many problems. Among them, the development of drug resistance is considered as one of the important reasons that limit the clinical application of PARP inhibitors. Introduction PARP-1 function and PARP-1 inhibitor research progress, focusing on the clinical manifestations of PARP-1 inhibitor resistance, possible mechanisms and reversal strategies for the clinical rational use of PARP-1 inhibitors provide a reference.